scholarly journals Damar İçi Madde Bağımlılığı Olan ve Madde Bağımlısı Olmayan Hastalar Arasında Hepatit C Virus (HCV) Genotiplerinin Dağılımı

2021 ◽  
Vol 55 (1) ◽  
pp. 30-40
Author(s):  
Aylin Erman Daloğlu ◽  
Ömür Mustafa Parkan ◽  
Ali Erdoğan ◽  
Bilal Olcay Peker ◽  
Rabia Can Sarınoğlu ◽  
...  
Keyword(s):  
Drug Users ◽  
Hcv Rna ◽  
Genotype Distribution ◽  
Plasma Samples ◽  
Genotype 1 ◽  
Mixed Genotype ◽  
Hcv Genotype ◽  
Genotype 1B ◽  
Hcv Genotyping ◽  
Genotype 3A

Genotype distribution of hepatitis C virus (HCV) can vary over the years between different patient groups and regions. The prevalence of intravenous drug users (IVDU) is known to increase in our country, yet there are a limited number of studies investigating the distribution of HCV genotypes in this group. These data are essential for monitorization of the changes in HCV epidemiology. The present study aimed to evaluate the five-year results of HCV genotyping among patients infected with HCV related to IVDU and unrelated to drug use. Plasma samples of 720 patients (HCV antibody, HCV RNA positive), which were sent to our laboratory for HCV genotyping between January 2014-March 2019 were analyzed. HCV RNA extraction from plasma samples was performed in the automated-extraction system of EZ1 advanced (Qiagen, Germany) using the EZ1 virus mini kit v2.0 (Qiagen, Germany). Amplicons were obtained by amplifying the 5’NCR and core gene region in the Rotorgene 6000 real-time PCR (Qiagen, Germany) device with the HCV RNA real-time quantitative 2.0 (NLM, Italy) kit. For the genotyping, a commercial line probe assay (LIPA) based on in vitro reverse hybridization GEN-C2.0 kit (NLM, Italy) which can distinguish 1, 2, 3, 4, 6 genotypes and 1a, 1b, 2a/c, 2b, 3a, 3b, 3c, 3k, 4a, 4b, 4c/d, 4e, 4f, 4h, 5a, 6a/b, 6g, 6f/q, 6m, 7a subtypes of HCV, based on variations in the 5’-NCR and core regions was used. HCV genotype distribution of 266 IVDU (93.2%: male; median age: 25 ± 6.82) and 454 non-drug users (51.3%: male; median age: 56.5 ± 16.06) were examined. In order of frequency in the group with IVDU; genotype 1a, 3a, 1b, 4c/d, 2b, 4, 3 were observed and genotype 1, 2a/c and mixed genotype (1+3a) were detected in one patient. In the group without IVDU, in order of frequency; genotype 1b, 1a, 3a, 1, 2a/c, 4 were observed and genotype 2b, 4c/d, 5a, 6a/b, 6 and mixed genotype (3+4) were detected in one patient. Genotypes 1a and 3a were significantly higher in the IVDU group (p< 0.00001, p< 0.00001), while 1b was significantly higher in patients without IVDU (p< 0.00001). Genotypes 1a and 3a were more common in young men (p< 0.00001, p= 0.000163), while 1b was higher in middleaged women (p< 0.00001). The incidence of genotypes 1b (p= 0.021) and 3a (p= 0.012) was higher in foreign nationals than the Turkish patients. When the HCV genotype distribution was examined by years, it was observed that the percentages of genotype 1b and 1a were decreasing, while the percentage of genotype 3a was increasing. As a result, in this study, HCV genotype distribution among IVDU was observed to be different from the general population without IVDU. It was found that genotypes 1a and 3a were more common in the IVDU group. As in the other regions of our country, genotype 1b was found most frequently in the general population. Genotype 3a increases significantly compared to years. In our study, the determination of genotypes existing in different parts of the world may be due to the foreign nationals living in our city and our region is a tourism center. It is also necessary to investigate whether there is an increase in IVDU over the years.

The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders

Blood ◽  
2001 ◽  
Vol 98 (6) ◽  
pp. 1836-1841 ◽  
Author(s):  
Massimo Franchini ◽  
Gina Rossetti ◽  
Annarita Tagliaferri ◽  
Franco Capra ◽  
Elena de Maria ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hcv Rna ◽  
Genotype Distribution ◽  
Bleeding Disorders ◽  
Genotype 1 ◽  
Hepatic Decompensation ◽  
Hcv Genotype ◽  
Hiv Negative

Abstract This study looked at 102 anti–hepatitis C virus (HCV)–positive, hepatitis B virus (HBV)–negative, and HIV-negative patients (median age, 45.1 years; range, 15-71) affected by hereditary bleeding disorders who have been infected with HCV for 15 to 34 years (median, 25.1). All these patients were infected before the mid 1980s because of non–virally inactivated pooled blood products. Fourteen patients (13.7%) were HCV-RNA negative with no signs of liver disease and were considered to have cleared the virus. Eighty-eight patients (86.3%) were HCV-RNA positive. The HCV genotype distribution was 1a in 20.5%, 1b in 36.4%, 2 in 17.0%, 3 in 15.9%, 4 in 3.4%, and mixed in 6.8% of cases. Twenty-four patients (23.5%) had serum cryoglobulins, symptomatic in 4 cases, and associated with liver disease and with genotype 1. Among the 88 HCV-RNA–positive patients, 15 (17.0%) had normal alanine aminotransferase levels and abdominal ultrasound, 61 (69.3%) had nonprogressive chronic hepatitis, and 12 (13.7%) had severe liver disease (6 [6.9%] liver cirrhosis, 4 [4.5%] hepatic decompensation, and 2 [2.3%] hepatocellular carcinoma) after a follow-up period of 25 years. There were 3 (3.4%) liver-related deaths. HCV genotype 1, patient's age at evaluation, duration of infection, and severity of congenital bleeding disorder were associated with more advanced liver disease. The results confirm the slow progression of HCV infection in HIV-negative hemophiliacs.

scholarly journals Hepatitis C Genotypes in Patients with Chronic Hepatitis C Infection: A Three-Year Evaluation

2020 ◽  
Vol 25 (3) ◽  
pp. 347-353
Author(s):  
Yasemin Derya Gülseren ◽  
Fatma Esenkaya Taşbent ◽  
Mehmet Özdemir ◽  
Bahadır Feyzioğlu
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hcv Rna ◽  
Genotype Distribution ◽  
Hepatitis C Infection ◽  
Genotype 1B ◽  
Geographical Regions ◽  
Genotype 3A

Introduction: In case of chronic hepatitis C infection, cirrhosis and hepatocellular carcinoma may progress. HCV genotypes and subtypes have been found to vary according to geographical regions. In addition to its epidemiological importance, HCV genotype is an important factor in determining the response and duration of treatment. In this study, it was aimed to determine the genotype distribution in our region. Materials and Methods: The results of 241 patients with HCV RNA positivity detected in our laboratory Molecular unit between 2016 and 2018 were retrospectively screened. HCV-RNA extraction for genotyping was performed by automated system (EZ1 Virus Mini Kit v.2.0, Germany), and ‘’line probe assay’’ (LIPA) based on reverse hybridization method was applied. HCV-RNA levels were determined by real-time PCR method (Artus HCV QS-RGQ kit, Qiagen, Germany). Results: Two hundred and forty-one patients were included in the study, and 116 (48%) were females and 125 (52%) were males. Mean age was 56.1 ± 19.4 (range: 16-90) years. Mean logarithmic viral load value was 5.7 ± 0.9 IU/ml (range; 2.71 x 102-17 x 106), mean value of AST was 50.5 ± 43.7 IU/ml and mean ALT value was 63.4 ± 63.5 IU/ml. Genotype 1b was detected in 58.9% of the patients, genotype 3a in 14.1%, genotype 1a in 13.27%, genotype 2b in 4.1%, genotype 4a in 1.2%. The subtypes could not be determined for 4.9%, 1.2%, 1.6% and 0.4% of infected patient in genotype 1,2,4 and 5 respectively. Conclusion: In our study, genotype 1b (58.9%) was found as the dominant genotype. This was followed by genotype 3a (14.1%). In patients infected with genotype 1, viral load value was found to be significantly higher than other genotypes. Monitoring genotype change is important for determining treatment protocols and duration.

scholarly journals Giresun İli Hepatit C Hastalarında Genotip Dağılımının Araştırılması

2020 ◽  
Vol 25 (4) ◽  
pp. 549-554
Author(s):  
Serpil Genç ◽  
Mediha Uğur ◽  
Emel Uzunoğlu Karagöz ◽  
Esin Avcı
Keyword(s):  
Public Health Problem ◽  
Distribution Data ◽  
Hcv Rna ◽  
Genotype Distribution ◽  
Hcv Genotype ◽  
Hcv Genotypes ◽  
Genotype 1B ◽  
Genotype 2 ◽  
Significant Difference ◽  
Rna Levels

Introduction: HCV infections are an important public health problem due to their high chronicity, cirrhosis and advanced complications like hepatocellular carcinoma. In HCV infections, it is important and necessary to determine genotypes before treatment because treatment times and protocols vary according to genotypes. The aim of this study was to determine the distribution of HCV genotypes in HCV-RNA positive individuals in Giresun province and to investigate whether there was a statistically significant difference between genotypes and patient ages. Materials and Methods: HCV-RNA level and HCV genotype of 147 patients were included in the study. HCV RNA levels of the samples were studied by QIAsymphony SP (Qiagen) automated device, genotype determination by Rotor Gene Q (Qiagen) automated device by “real-time polymerase chain reaction (PCR)” method. Each sample was tested for HCV genotypes 1a, 1b, 2, 3, 4, 5a and 6. Results: Of the 147 patients genotyped; 128 (87%) genotype 1b, 9 (6%) genotype 1a, 8 (6%) genotype 3, 2 (1%) genotype 2 were detected. Genotypes 4, 5a and 6 were not detected. According to the HCV genotype distribution, median age and range (min.-max.) of the patients weren50 (30-83) for 1a, 70 (22-87) for 1b, 48.5 (36-61) for 2 and 33 (25-52) for 3. HCV RNA levels were between 37 and 12.630.170 IU/mL. Conclusion: The predominant genotype in the world and Turkey is genotype 1b. In our study, the most common genotype was also genotype 1b (87%), consistent with other studies in our country. This study contributed to HCV genotype distribution data in our region and country.

Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study

2010 ◽  
Vol 28 (30) ◽  
pp. 4587-4593 ◽  
Author(s):  
Lee Mei-Hsuan ◽  
Hwai-I Yang ◽  
Sheng-Nan Lu ◽  
Chin-Lan Jen ◽  
Shiou-Hwei Yeh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Elevated Serum ◽  
Hcv Rna ◽  
Genotype 1 ◽  
Hcv Genotype ◽  
Hcv Genotype 1 ◽  
Carcinoma Risk

Purpose Hepatitis C virus (HCV) contributes to one third of hepatocellular carcinoma cases worldwide. Long-term predictors for HCV-related hepatocellular carcinoma are essential for early intervention. Serum HCV RNA and ALT levels and HCV genotype were assessed for their predictability of hepatocellular carcinoma risk. Methods A prospective cohort of 925 participants positive for antibodies against HCV and age 30 to 65 years was recruited and followed from 1991 to 2006. Serum HCV RNA and ALT levels and HCV genotypes at enrollment and during follow-up were examined. Newly developed hepatocellular carcinoma was identified by health examination and computerized linkage with national cancer registration and death certification profiles. Multivariate adjusted hazard ratios with 95% CIs were estimated using Cox regression models. Results Fifty-five participants newly developed hepatocellular carcinoma during 8,476 person-years of follow-up, giving an incidence rate of 648.9 per 100,000 person-years. The cumulative hepatocellular carcinoma risk increased from 1.1% for HCV RNA seronegative status to 6.4% for low HCV RNA levels and to 14.7% for high HCV RNA levels (P < .001). The cumulative risk also increased with elevated serum ALT levels from 1.7% for persistently ≤ 15 U/L to 4.2% for ever more than 15 U/L but never more than 45 U/L and to 13.8% for ALT ever ≥ 45 U/L (P < .001). Having HCV genotype 1 was associated with a higher cumulative hepatocellular carcinoma risk (12.6%) than not having HCV genotype 1 (4.5%; P < .001). Conclusion Elevated serum levels of HCV RNA and ALT and HCV genotype 1 infection are independent risk predictors of hepatocellular carcinoma. These findings have strong implications for the management of chronic HCV.

scholarly journals ‘Distribution of Hepatitis C Virus genotypes in northern Greece in the last decade: descriptive analysis and clinical correlations’

2019 ◽  
Vol 4 ◽  
Author(s):  
G. Gioula ◽  
E. Sinakos ◽  
E. Gigi ◽  
I. Goulis ◽  
T. Vasiliadis ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Intravenous Drug ◽  
Genotype Distribution ◽  
Intravenous Drug Use ◽  
Genotype 1 ◽  
Genotype 3 ◽  
Northern Greece ◽  
Hcv Genotype

Abstract Hepatitis C virus (HCV) represents a major public health problem, while the identification of a HCV genotype is clinically very important for therapy prescription. The aim of the present study was to determine the HCV genotype distribution patients from northern Greece with HCV RNA positive viral load and to identify whether there is a shift in this distribution, during 2009–2017. The study was performed on 915 HCV positive patients and according to the results, genotype 3 was the most prevalent genotype (Ν = 395, 43.2%) followed by genotype 1 (Ν = 361, 39.5%). Regarding the gender of the patients, genotype 1 was mostly detected in women. Moreover, genotype 1 was associated with higher viral loads, while genotype 3 was most frequently detected in patients with a history of intravenous drug use. In conclusion, our results show that genotype 3 is the most prevalent genotype in Greece during the last decade as opposed to older epidemiological studies, likely due to intravenous drug use becoming the major source of infection.

Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir

2015 ◽  
Vol 72 ◽  
pp. 133-140 ◽  
Author(s):  
Bart Fevery ◽  
Simone Susser ◽  
Oliver Lenz ◽  
Gavin Cloherty ◽  
Dany Perner ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Hcv Rna ◽  
Genotype 1 ◽  
Hcv Genotype ◽  
Hcv Genotype 1

scholarly journals Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

2014 ◽  
Vol 58 (6) ◽  
pp. 3496-3503 ◽  
Author(s):  
Karen D. Sims ◽  
Julie Lemm ◽  
Timothy Eley ◽  
Menping Liu ◽  
Anna Berglind ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Hcv Rna ◽  
Genotype 1 ◽  
Hcv Genotype ◽  
Dose Study ◽  
Hcv Genotype 1 ◽  
Hcv Ns5b ◽  
Ns5b Polymerase ◽  
Single Ascending Dose Study

ABSTRACTBMS-791325 is a nonnucleoside inhibitor of hepatitis C virus (HCV) NS5B polymerase with low-nanomolar potency against genotypes 1a (50% effective concentration [EC50], 3 nM) and 1b (EC50, 7 nM)in vitro. BMS-791325 safety, pharmacokinetics, and antiviral activity were evaluated in a double-blind, placebo-controlled, single-ascending-dose study in 24 patients (interferon naive and experienced) with chronic HCV genotype 1 infection, randomized (5:1) to receive a single dose of BMS-791325 (100, 300, 600, or 900 mg) or placebo. The prevalence and phenotype of HCV variants at baseline and specific posttreatment time points were assessed. Antiviral activity was observed in all cohorts, with a mean HCV RNA decline of ≈2.5 log10copies/ml observed 24 h after a single 300-mg dose. Mean plasma half-life among cohorts was 7 to 9 h; individual 24-hour levels exceeded the protein-adjusted EC90for genotype 1 at all doses. BMS-791325 was generally well tolerated, with no serious adverse events or discontinuations. Enrichment for resistance variants was not observed at 100 to 600 mg. At 900 mg, variants (P495L/S) associated with BMS-791325 resistancein vitrowere transiently observed in one patient, concurrent with an observed HCV RNA decline of 3.4 log10IU/ml, but were replaced with wild type by 48 h. Single doses of BMS-791325 were well tolerated; demonstrated rapid, substantial, and exposure-related antiviral activity; displayed dose-related increases in exposure; and showed viral kinetic and pharmacokinetic profiles supportive of once- or twice-daily dosing. These results support its further development in combination with other direct-acting antivirals for HCV genotype 1 infection. (This trial has been registered at ClinicalTrials.gov under registration no. NCT00664625.)

scholarly journals HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients

2017 ◽  
Vol 245 ◽  
pp. 14-18 ◽  
Author(s):  
Jürgen Kurt Rockstroh ◽  
Jordan J. Feld ◽  
Stéphane Chevaliez ◽  
Kevin Cheng ◽  
Heiner Wedemeyer ◽  
...  
Keyword(s):  
Core Antigen ◽  
Hcv Rna ◽  
Genotype 1 ◽  
Hcv Genotype ◽  
Hcv Core Antigen ◽  
Free Treatment ◽  
Alternate Test ◽  
Hcv Genotype 1

scholarly journals Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

2015 ◽  
Vol 59 (11) ◽  
pp. 6922-6929 ◽  
Author(s):  
Rong Liu ◽  
Stephanie Curry ◽  
Patricia McMonagle ◽  
Wendy W. Yeh ◽  
Steven W. Ludmerer ◽  
...  
Keyword(s):  
Amino Acid ◽  
Hcv Rna ◽  
Dependent Manner ◽  
Genotype 1 ◽  
Genotype 3 ◽  
Ns5a Inhibitor ◽  
Genotype 1A ◽  
Genotype 1B ◽  
Ns5a Ravs

ABSTRACTElbasvir is an investigational NS5A inhibitor within vitroactivity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes 1a, 1b, and 3. The barrier to resistance was assessed by the number of resistant colonies selected by exposure to various elbasvir concentrations. In a phase 1b dose-escalating study, virologic responses were determined in 48 noncirrhotic adult men with chronic genotype 1 or 3 infections randomized to placebo or elbasvir from 5 to 50 mg (genotype 1) or 10 to 100 mg (genotype 3) once daily for 5 days. The NS5A gene was sequenced from plasma specimens obtained before, during, and after treatment. Elbasvir suppressed the emergence of resistance-associated variants (RAVs)in vitroin a dose-dependent manner. Variants selected by exposure to high elbasvir concentrations typically encoded multiple amino acid substitutions (most commonly involving loci 30, 31, and 93), conferring high-level elbasvir resistance. In the monotherapy study, patients with genotype 1b had greater reductions in HCV RNA levels than patients with genotype 1a at all elbasvir doses; responses in patients with genotype 3 were generally less pronounced than for genotype 1, particularly at lower elbasvir doses. M28T, Q30R, L31V, and Y93H in genotype 1a, L31V and Y93H in genotype 1b, and A30K, L31F, and Y93H in genotype 3 were the predominant RAVs selected by elbasvir monotherapy. Virologic findings in patients were consistent with the preclinical observations. NS5A-RAVs emerged most often at amino acid positions 28, 30, 31, and 93 in both the laboratory and clinical trial. (The MK-8742 P002 trial has been registered at ClinicalTrials.gov under identifier NCT01532973.)

Sign in / Sign up

Export Citation Format

Share Document